Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Yves Fradet

Full professor

Laval University

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Immunology Immunology professors in Canada

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (34)

Vincent Fradet

Full Professor

Université Laval Faculté de médecine

CANADA

View details

Carole Harris

University of New South Wales

AUSTRALIA

View details

Mitchell Elliott

University of Toronto

CANADA

View details

Afshin Raouf

Associate Professor

University of Manitoba

CANADA

View details

Job van Riet

NETHERLANDS

View details

David Dix

Clinical Professor

The University of British Columbia

CANADA

View details

Saima Hassan

Associate Professor

Centre Hospitalier de l'Université de Montréal Centre de Recherche

CANADA

View details

Etienne Audet-Walsh

Associate Professor

Laval University

CANADA

View details

Michael J. Monument

University of Calgary

CANADA

View details

Peter Georgeson

University of Melbourne

AUSTRALIA

View details

Howard Gurney

Macquarie University

AUSTRALIA

View details

Christof Vulsteke

University of Antwerp

BELGIUM

View details

Pedro Farinha

Clinical Professor

The University of British Columbia

CANADA

View details

Sabrina Wurzba

Principal Investigator

McGill University Faculty of Medicine

CANADA

View details

Hyojin Song

Bioinformatics Specialist

University of Calgary

CANADA

View details

Touati Benoukraf

Canada Research Chair | Tier II

Memorial University of Newfoundland

CANADA

View details

Jennifer Chan

Broad Institute

UNITED STATES

View details

Lisa A. Porter

Distinguished Professor

University of Windsor

CANADA

View details

Weerachai Jaratlerdsiri

Group Leader

University of Sydney

AUSTRALIA

View details

lucia nappi

Assistant Professor

The University of British Columbia

CANADA

View details

Caroline Diorio

Professor

Laval University

CANADA

View details

Juliette Hukin

Clinical Associate Professor

The University of British Columbia

CANADA

View details

Kathleen Houlahan

McMaster University

CANADA

View details

Marco Gallo

Associate Professor

Baylor College of Medicine

UNITED STATES

View details

Jaron Arbet

Research Assistant Professor - Biostatistician

City Of Hope National Medical Center

UNITED STATES

View details

Ram Mani

Associate Professor

University of Texas Southwestern Medical Center

UNITED STATES

View details

Joon Seon Lee

Assistant Professor

Brigham Young University

UNITED STATES

View details

Robert Bristow

The University of Manchester

UNITED KINGDOM

View details

Graham Dellaire

Professor

Dalhousie University Faculty of Medicine

CANADA

View details

Pavlina Spiliopoulou

University of Glasgow

UNITED KINGDOM

View details

Javier Puente

Head of the GU Cancer Unit

Hospital Clínico San Carlos

SPAIN

View details

Darrell Underhill

Associate Professor

University of Alberta

CANADA

View details

Sujun Chen

Principal Investigator

Sichuan University

CHINA

View details

Avram Denburg

Associate Professor (Status-Only)

University of Toronto

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yves Fradet

Research Interests

Explore related searches

Articles (20)

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

New insights into gut microbiota–prostate cancer crosstalk

Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study

The Germline and Somatic Origins of Prostate Cancer Heterogeneity

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

The landscape of N&lt;sup&gt;6&lt;/sup&gt;-methyladenosine in localized primary prostate cancer.

A versatile and efficient method to isolate nuclei from low-input cryopreserved tissues for single-nuclei transcriptomics.

Feasibility and acceptability of a personalised primary prevention strategy for women and men at high risk of breast and prostate cancer: the 3PC study protocol for a pilot randomised controlled trial.

2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer.

Association des Urologues du Québec Congrès Annuel 2024 - Résumés Session scientifique IVVendredi 8 novembre 2024 • Friday, November 8, 2024.

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.

Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes.

The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression.

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids.

A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation.

Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC.

Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial.

Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.

Collaborators (34)

Vincent Fradet

Carole Harris

Mitchell Elliott

Afshin Raouf

Job van Riet

David Dix

Saima Hassan

Etienne Audet-Walsh

Michael J. Monument

Peter Georgeson

Howard Gurney

Christof Vulsteke

Pedro Farinha

Sabrina Wurzba

Hyojin Song

Touati Benoukraf

Jennifer Chan

Lisa A. Porter

Weerachai Jaratlerdsiri

lucia nappi

Caroline Diorio

Juliette Hukin

Kathleen Houlahan

Marco Gallo

Jaron Arbet

Ram Mani

Joon Seon Lee

Robert Bristow

Graham Dellaire

Pavlina Spiliopoulou

Javier Puente

Darrell Underhill

Sujun Chen

Avram Denburg

Make your next move.

The landscape of N<sup>6</sup>-methyladenosine in localized primary prostate cancer.